Insider Selling: Cardlytics, Inc. (NASDAQ:CDLX) CFO Sells $86,154.74 in Stock

Cardlytics, Inc. (NASDAQ:CDLX) CFO Alexis Desieno sold 25,118 shares of the firm’s stock in a transaction on Friday, November 15th. The stock was sold at an average price of $3.43, for a total value of $86,154.74. Following the transaction, the chief financial officer now owns 116,481 shares in the company, valued at $399,529.83. This trade represents a 17.74 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Alexis Desieno also recently made the following trade(s):

• On Wednesday, October 2nd, Alexis Desieno sold 7,487 shares of Cardlytics stock. The stock was sold at an average price of $3.08, for a total transaction of $23,059.96.

Cardlytics Stock Performance

Shares of CDLX stock opened at $3.38 on Monday. Cardlytics, Inc. has a 12-month low of $2.89 and a 12-month high of $20.52. The company has a debt-to-equity ratio of 2.40, a current ratio of 1.18 and a quick ratio of 1.18. The firm has a market capitalization of $171.78 million, a price-to-earnings ratio of -0.55 and a beta of 1.61. The business has a 50 day simple moving average of $3.72 and a 200 day simple moving average of $6.33.

Cardlytics (NASDAQ:CDLX) last released its quarterly earnings results on Wednesday, November 6th. The company reported ($0.15) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.33) by $0.18. Cardlytics had a negative return on equity of 110.67% and a negative net margin of 93.55%. The company had revenue of $67.06 million during the quarter, compared to analysts’ expectations of $57.77 million. During the same quarter in the prior year, the business posted ($0.26) earnings per share. The company’s revenue for the quarter was down 15.1% compared to the same quarter last year. On average, equities research analysts anticipate that Cardlytics, Inc. will post -1.52 EPS for the current year.

Hedge Funds Weigh In On Cardlytics

Large investors have recently bought and sold shares of the stock. Vanguard Group Inc. lifted its stake in shares of Cardlytics by 2.7% in the 1st quarter. Vanguard Group Inc. now owns 2,211,595 shares of the company’s stock worth $32,046,000 after acquiring an additional 57,805 shares during the period. Geode Capital Management LLC lifted its position in Cardlytics by 7.5% in the third quarter. Geode Capital Management LLC now owns 1,053,178 shares of the company’s stock worth $3,371,000 after purchasing an additional 73,484 shares during the period. Marshall Wace LLP lifted its position in Cardlytics by 6.8% in the second quarter. Marshall Wace LLP now owns 814,281 shares of the company’s stock worth $6,685,000 after purchasing an additional 52,081 shares during the period. RBF Capital LLC boosted its stake in Cardlytics by 311.9% during the 3rd quarter. RBF Capital LLC now owns 488,128 shares of the company’s stock valued at $1,562,000 after purchasing an additional 369,620 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. increased its position in shares of Cardlytics by 3.0% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 390,343 shares of the company’s stock valued at $1,249,000 after purchasing an additional 11,388 shares during the period. Institutional investors and hedge funds own 68.10% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts recently weighed in on the stock. Northland Capmk lowered shares of Cardlytics from a “strong-buy” rating to a “hold” rating in a research note on Friday, August 16th. Bank of America cut Cardlytics from a “neutral” rating to an “underperform” rating and dropped their price target for the stock from $4.00 to $3.50 in a research report on Thursday, August 15th. Evercore ISI initiated coverage on Cardlytics in a research report on Friday, October 11th. They set an “in-line” rating and a $4.00 price objective for the company. Needham & Company LLC reaffirmed a “hold” rating on shares of Cardlytics in a research report on Thursday, November 7th. Finally, Northland Securities cut Cardlytics from an “outperform” rating to a “market perform” rating and cut their target price for the company from $7.00 to $5.00 in a research note on Friday, August 16th. One investment analyst has rated the stock with a sell rating, five have given a hold rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $6.92.

Cardlytics Company Profile

Cardlytics, Inc operates an advertising platform in the United States and the United Kingdom. It offers Cardlytics platform, a proprietary native bank advertising channel that enables marketers to reach customers through their network of financial institution partners through digital channels, such as online, mobile applications, email, and various real-time notifications; and Bridg platform, a customer data platform which utilizes point-of-sale data and enables marketers to perform analytics and targeted loyalty marketing, as well as measure the impact of their marketing.